I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Biostage (BSTG) de-listing determination

December 7, 2017

Effective at the opening of the trading session on December 18, 2017 as communicated 12/7/17 Another shovel of dirt to its grave, shame on them ... incompetance at its worst!

Biostage (BSTG) the end is in sight with a lab liquidation auction, next the lights get turned off

December 6, 2017

$30 M of shareholder monies down the drain by a “gang that couldn’t talk “straight” or execute Where are “these” dollars going, certainly NOT to shareholders who are left with an empty bag!

Cesca Therapeutics (KOOL) proposes 900 K share offering priced at $3.00

November 28, 2017

KOOL closed down -$0.36 or -10.29% to $3.14 with a market open price -$0.22 or -6.97% to $2.93

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.